NovoCure Ltd — Director's Dealing 2022

Mar 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-03-03

Reporting Person: DOYLE WILLIAM F (Director, Executive Chairman)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-03	Options to Buy Ordinary Shares	$80.59	A	14581	Acquired	2032-02-29	Ordinary Shares (14581.0)	Direct

Footnotes

F1: Options to buy 14,581 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.